Shield Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	49.7	32.18	13.09	5.5	2.05
Revenue Growth	54.45%	145.93%	137.95%	167.76%	-85.54%
Cost of Revenue	26.66	17.25	9.06	3.04	1.32
Gross Profit	23.04	14.93	4.03	2.46	0.73
Selling, General & Admin	31.59	36.01	37.96	33.65	27.24
Research & Development	1.54	1.89	1.81	1.32	1.07
Other Operating Expenses	-0.04	-0.1	-4.41	17.24	-0.15
Total Operating Expenses	33.09	37.8	35.36	52.21	28.17
Operating Income	-10.05	-22.87	-31.33	-49.75	-27.44
Interest Income	0.33	0.27	0.52	0.89	0.53
Interest Expense	-7.42	-3.95	-1.56	-0.48	-0.01
Total Non-Operating Income (Expense)	-7.09	-3.68	-1.04	0.41	0.52
Pretax Income	-17.14	-26.56	-32.38	-49.34	-26.91
Provision for Income Taxes	0.51	0.63	0.92	0.45	-0.31
Net Income	-17.66	-27.18	-33.29	-49.79	-26.6
Net Income to Common	-17.66	-27.18	-33.29	-49.79	-26.6
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	1,047	783	723	233	204
Shares Outstanding (Diluted)	1,047	783	723	233	204
Shares Change	33.81%	8.33%	209.85%	14.08%	74.36%
EPS (Basic)	-0.02	-0.03	-0.05	-0.21	-0.14
EPS (Diluted)	-0.02	-0.03	-0.05	-0.21	-0.14
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-3.4	-6.81	-37.37	-22.66	-25.19
Free Cash Flow Growth	-	-	-	-	-
Free Cash Flow Per Share	-0.00	-0.01	-0.05	-0.10	-0.12
Gross Margin	46.36%	46.40%	30.78%	44.70%	35.48%
Operating Margin	-20.22%	-71.08%	-239.44%	-904.75%	-1336.01%
Profit Margin	-35.52%	-84.47%	-254.44%	-905.42%	-1295.46%
FCF Margin	-6.85%	-21.15%	-285.56%	-411.98%	-1226.73%
EBITDA	-8.94	-21.45	-30.26	-47.09	-24.45
EBITDA Margin	-17.98%	-66.65%	-231.26%	-856.34%	-1190.72%
EBIT	-10.05	-22.87	-31.33	-49.75	-27.44
EBIT Margin	-20.22%	-71.08%	-239.44%	-904.75%	-1336.01%
Effective Tax Rate	-3.00%	-2.36%	-2.84%	-0.90%	1.15%